Isolation of amniotic stem cell lines with potential for therapy (Nat Biotechnol, 2007, 25:100-106)

報告日期: 2007/11/27
報告時間: 16:10/17:00
報告學生: 高久晴
講評老師: 謝清河
附件下載:

http://basicmed.med.ncku.edu.tw/upload_data/961127-2.pdf

Time: 2007/11/27, 16:10-17:00

Commentator: Dr. 謝清河

Speaker: 高久晴

Place: 602

Isolation of amniotic stem cell lines with potential for therapy

 

Paolo De Coppi, Georg Bartsch, Jr1, M Minhaj Siddiqui, Tao Xu, Cesar C Santos, Laura Perin, Gustavo Mostoslavsky, Ange´line C Serre, Evan Y Snyder, James J Yoo, Mark E Furth, Shay Soker & Anthony Atala1                                          Wake Forest University School of Medicine

 

 

Nature Biotechnology Volume 25 Number 1 January 2007 P100-106

 

Amniotic fluid (AF) cells are used for the prenatal diagnosis of a wide range of fetal abnormalities (chromosomal, biochemical, structural, genetic), but despite the technological advances in their use as diagnostic tools little is known of their origins, circulation or lifespan.1

  Human amniotic fluid as a potential new source of stem cell was first reported in 2003.2  However, the type of amniotic fluid–derived stem (AFS) cells are yet to be fully understood. This study showed that AFS cells are pluripotent and express embryonic and adult stem cell markers. AFS could be induced to differentiate into cell types representing each embryonic germ layer, including cells of adipogenic, osteogenic, myogenic, endothelial, neuronal and hepatic lineages. The authors also demonstrated that human AFS cells repaired damaged neuronal, bone tissue, and were not tumorigenic. In conclusion, AFS cells hold potential for a variety of therapeutic applications in the future.

 

 

References:

 

1. Amniotic cell types and culture.British Medical Bulletin 1983; 39: 348-354.

2. Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research?

 Human Reproduction 2003; 18: 1489–1493.